Where the Comment is King

THE NEWS COMMENTER

VOTE  (0)  (0)

UK health minister says data on Pfizer vaccine supports shift to 12-week dosing schedule

Added 01-21-21 07:04:03am EST - “Data supports Britain's decision to move to a 12-week dosing schedule for Pfizer's COVID vaccine, health minister Matt Hancock said on Thursday, adding details on efficacy gathered during the rollout would be published as soon as…” - News.yahoo.com

CLICK TO SHARE

Posted By TheNewsCommenter: From News.yahoo.com: “UK health minister says data on Pfizer vaccine supports shift to 12-week dosing schedule”. Below is an excerpt from the article.

LONDON (Reuters) - Data supports Britain's decision to move to a 12-week dosing schedule for Pfizer's COVID vaccine, health minister Matt Hancock said on Thursday, adding details on efficacy gathered during the rollout would be published as soon as possible.

"Around 89% efficacy comes from between days 14 and days 21 after the first dose," Hancock told lawmakers, saying he had reviewed the data, and that it supported the decision to move to a 12-week schedule between doses.

"We're looking at this data, and in fact we're measuring the efficacy here at home for those who've been vaccinated, by matching the data between those who've been vaccinated and those who test positive. And we're monitoring that and we will publish that data as soon as it is clinically valid."

Fresh off his inauguration Wednesday, President Biden began his term with executive orders on measures ranging from curbing the coronavirus pandemic to addressing racial inequality, many of which roll back measures enacted by former President Donald Trump’s administration.

On the eve of President-elect Joe Biden’s inauguration, freshman Rep. Marjorie Taylor Greene, the combative Georgia Republican known for her association with QAnon, was back on Twitter after a 12-hour suspension, and back to making waves. 

Read more...

If you don't see any comments yet, congrats! You get first comment. Be nice and have fun.

CLICK TO SHARE

BACK TO THE HOME-PAGE